156 related articles for article (PubMed ID: 35698011)
21. A Review of Oral Semaglutide Available Evidence: A New Era of Management of Diabetes with Peptide in a Pill Form.
Kalra S; Das S; Zargar AH
Indian J Endocrinol Metab; 2022; 26(2):98-105. PubMed ID: 35873937
[TBL] [Abstract][Full Text] [Related]
22. Identification of a Multi-Component Formulation for Intestinal Delivery of a GLP-1/Glucagon Co-agonist Peptide.
Tran H; Patel PJ; Aburub A; Sperry A; Estwick S; ElSayed MEH; -Mannan AD
Pharm Res; 2022 Oct; 39(10):2555-2567. PubMed ID: 36050547
[TBL] [Abstract][Full Text] [Related]
23. Oral Semaglutide in the Management of Type 2 DM: Clinical Status and Comparative Analysis.
Bandyopadhyay I; Dave S; Rai A; Nampoothiri M; Chamallamudi MR; Kumar N
Curr Drug Targets; 2022; 23(3):311-327. PubMed ID: 34468297
[TBL] [Abstract][Full Text] [Related]
24. Cardiovascular safety and benefits of GLP-1 receptor agonists.
Dalsgaard NB; Brønden A; Vilsbøll T; Knop FK
Expert Opin Drug Saf; 2017 Mar; 16(3):351-363. PubMed ID: 28102093
[TBL] [Abstract][Full Text] [Related]
25. Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6.
Nauck MA; Quast DR
Front Endocrinol (Lausanne); 2021; 12():645566. PubMed ID: 33854484
[TBL] [Abstract][Full Text] [Related]
26. Sgemaglutide in type 2 diabetes - is it the best glucagon-like peptide 1 receptor agonist (GLP-1R agonist)?
Doggrell SA
Expert Opin Drug Metab Toxicol; 2018 Mar; 14(3):371-377. PubMed ID: 29439603
[TBL] [Abstract][Full Text] [Related]
27. Relationship Between Oral Semaglutide Tablet Erosion and Pharmacokinetics: A Pharmacoscintigraphic Study.
Baekdal TA; Donsmark M; Hartoft-Nielsen ML; Søndergaard FL; Connor A
Clin Pharmacol Drug Dev; 2021 May; 10(5):453-462. PubMed ID: 33750044
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and Cardiovascular Safety of GLP-1 Receptor Analogues.
Iqbal AM; Imamudeen N; Basheer A; Menon S; Mohan G; Sani TN; Haroon NN
Curr Drug Saf; 2021; 16(2):197-206. PubMed ID: 33292155
[TBL] [Abstract][Full Text] [Related]
29. Oral semaglutide for the treatment of type 2 diabetes.
Hedrington MS; Davis SN
Expert Opin Pharmacother; 2019 Feb; 20(2):133-141. PubMed ID: 30499733
[TBL] [Abstract][Full Text] [Related]
30. Intestinal Permeation Enhancers for Oral Delivery of Macromolecules: A Comparison between Salcaprozate Sodium (SNAC) and Sodium Caprate (C
Twarog C; Fattah S; Heade J; Maher S; Fattal E; Brayden DJ
Pharmaceutics; 2019 Feb; 11(2):. PubMed ID: 30781867
[TBL] [Abstract][Full Text] [Related]
31. Discovery of once-weekly, peptide-based selective GLP-1 and cholecystokinin 2 receptors co-agonizts.
Zhou F; Song P; Tang X; Yang Q; Zhou S; Xu R; Fang T; Jia Z; Han J
Peptides; 2022 Jul; 153():170811. PubMed ID: 35594964
[TBL] [Abstract][Full Text] [Related]
32. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide.
Lau J; Bloch P; Schäffer L; Pettersson I; Spetzler J; Kofoed J; Madsen K; Knudsen LB; McGuire J; Steensgaard DB; Strauss HM; Gram DX; Knudsen SM; Nielsen FS; Thygesen P; Reedtz-Runge S; Kruse T
J Med Chem; 2015 Sep; 58(18):7370-80. PubMed ID: 26308095
[TBL] [Abstract][Full Text] [Related]
33. The role of oral semaglutide in managing type 2 diabetes in Indian clinical settings: Addressing the unmet needs.
Joshi SR; Rajput R; Chowdhury S; Singh AK; Bantwal G; Das AK; Unnikrishnan AG; Saboo BD; Kesavadev J; Ghosal S; Mohan V
Diabetes Metab Syndr; 2022 Jun; 16(6):102508. PubMed ID: 35653929
[TBL] [Abstract][Full Text] [Related]
34. Preference for Oral and Injectable GLP-1 RA Therapy Profiles in Japanese Patients with Type 2 Diabetes: A Discrete Choice Experiment.
Igarashi A; Bekker Hansen B; Langer J; Tavella F; Collings H; Davies N; Wyn R
Adv Ther; 2021 Jan; 38(1):721-738. PubMed ID: 33245530
[TBL] [Abstract][Full Text] [Related]
35. Current Understanding of Sodium N-(8-[2-Hydroxylbenzoyl] Amino) Caprylate (SNAC) as an Absorption Enhancer: The Oral Semaglutide Experience.
Solis-Herrera C; Kane MP; Triplitt C
Clin Diabetes; 2024; 42(1):74-86. PubMed ID: 38230324
[TBL] [Abstract][Full Text] [Related]
36. Long-acting GLP-1 receptor agonists: Findings and implications of cardiovascular outcomes trials.
Urquhart S; Willis S
JAAPA; 2020 Aug; 33(8):19-30. PubMed ID: 32740122
[TBL] [Abstract][Full Text] [Related]
37. Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect?
Li Y; Rosenblit PD
Curr Cardiol Rep; 2018 Sep; 20(11):113. PubMed ID: 30259238
[TBL] [Abstract][Full Text] [Related]
38. Semaglutide injection for the treatment of adults with type 2 diabetes.
Chudleigh RA; Bain SC
Expert Rev Clin Pharmacol; 2020 Jul; 13(7):675-684. PubMed ID: 32476529
[TBL] [Abstract][Full Text] [Related]
39. Long-acting GLP-1 receptor agonists: Findings and implications of cardiovascular outcomes trials.
Urquhart S; Willis S
JAAPA; 2020 Aug; 33(S8 Suppl 1):19-30. PubMed ID: 32756221
[TBL] [Abstract][Full Text] [Related]
40. Profile of semaglutide in the management of type 2 diabetes: design, development, and place in therapy.
Gomez-Peralta F; Abreu C
Drug Des Devel Ther; 2019; 13():731-738. PubMed ID: 30863012
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
